Physician profile
Robert H Davis
NPI 1851767552
$1,123.50
in general payments reported to CMS, 2019-2025
14 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $65.82 · 2021: $68.19 · 2022: $281 · 2023: $238 · 2024: $196 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.36 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $228.81 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.49 | 2019-2024 | Jardiance |
| La Jolla Pharmaceutical Company | $88.76 | 2022-2023 | Xerava |
| Pfizer INC. | $85.52 | 2021-2024 | |
| Abbvie INC. | $63.33 | 2023-2025 | Dalvance, Teflaro |
| Astrazeneca Pharmaceuticals LP | $41.30 | 2019-2021 | |
| Boston Scientific Corporation | $38.07 | 2023-2024 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $22.96 | 2025 | Nuzyra |
| Novo Nordisk INC | $18.82 | 2023 | |
| Merck Sharp & Dohme LLC | $17.63 | 2023 | Dificid, Zerbaxa |
| Irhythm Technologies, INC. | $16.54 | 2019 | |
| Enterra Medical, INC. | $15.62 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.